Table 3.
Univariable and multivariable Cox proportional hazards modeling of 10-year outcomes in the retrospective cohort analysis (n=193)
| Parameter | Univariable HR (95% CI) | P Value | Multivariable HR (95% CI) | P Value |
|---|---|---|---|---|
| Model A | ||||
| Cyclosporin-based regimen (tacrolimus as reference category) | 2.13 (1.01 to 4.46) | <0.05 | 1.98 (0.93 to 4.24) | 0.08 |
| Polyomavirus status (no BK/JC reactivation as reference category) | 0.96 (0.41 to 2.25) | 0.92 | ||
| Age at transplant, yr | 0.94 (0.92 to 0.97) | <0.001 | 0.94 (0.91 to 0.97) | <0.001 |
| HLA mismatches, number | 1.07 (0.88 to 1.33) | 0.56 | ||
| Black race (nonblack race as reference category) | 2.74 (1.20 to 6.25) | <0.05 | 1.87 (0.78 to 4.50) | 0.16 |
| Deceased donor type (living donor as reference category) | 1.99 (0.88 to 4.52) | 0.10 | 2.30 (0.96 to 5.51) | 0.06 |
| Men (women as reference category) | 1.14 (0.54 to 2.44) | 0.73 | ||
| Pretransplant diabetes (no diabetes as reference category) | 0.46 (0.16 to 1.31) | 0.15 | ||
| HCV positive (negative as reference category) | 4.08 (0.97 to 17.23) | 0.06 | 3.78 (0.83 to 17.14) | 0.09 |
| CMV viremia (no viremia as reference category) | 0.05 (0 to 10,166) | 0.63 | ||
| Model B | ||||
| Cyclosporin-based regimen (tacrolimus as reference category) | 0.88 (0.45 to 1.73) | 0.72 | ||
| Polyomavirus status (no BK/JC reactivation as reference category) | 1.84 (0.98 to 3.45) | 0.06 | 2.22 (1.10 to 4.49) | <0.05 |
| Age at transplant (yr) | 1.05 (1.02 to 1.08) | <0.001 | 1.04 (1.01 to 1.07) | <0.01 |
| HLA mismatches (number) | 1.21 (1.00 to 1.46) | <0.05 | 1.17 (0.96 to 1.44) | 0.13 |
| Black race (nonblack race as reference category) | 2.97 (1.51 to 5.82) | <0.01 | 3.18 (1.45 to 6.93) | <0.01 |
| Deceased donor type (living donor as reference category) | 2.48 (1.22 to 5.06) | 0.01 | 1.17 (0.96 to 1.44) | 0.07 |
| Men (women as reference category) | 0.94 (0.50 to 1.77) | 0.84 | ||
| Pretransplant diabetes (no diabetes as reference category) | 3.09 (1.67 to 5.69) | <0.001 | 2.35 (1.22 to 4.50) | 0.01 |
| HCV positive (negative as reference category) | 1.46 (0.20 to 10.62) | 0.71 | ||
| CMV viremia (no viremia as reference category) | 0.05 (0 to 791) | 0.54 | ||
| Model C | ||||
| Cyclosporin-based regimen (tacrolimus as reference category) | 2.66 (1.21 to 5.86) | <0.05 | 2.58 (1.15 to 5.80) | <0.05 |
| Polyomavirus status (no BK/JC reactivation as reference category) | 0.55 (0.19 to 1.60) | 0.27 | ||
| Age at transplant, yr | 0.93 (0.90 to 0.96) | <0.001 | 0.94 (0.90 to 0.97) | <0.001 |
| HLA mismatches, number | 1.21 (1.00 to 1.46) | <0.05 | 1.14 (0.89 to 1.46) | 0.31 |
| Black race (nonblack race as reference category) | 2.25 (0.90 to 5.64) | 0.09 | 1.15 (0.43 to 3.13) | 0.78 |
| Deceased donor type (living donor as reference category) | 1.19 (0.53 to 2.65) | 0.67 | ||
| Men (women as reference category) | 0.64 (0.27 to 1.53) | 0.31 | ||
| Pretransplant diabetes (no diabetes as reference category) | 0.26 (0.06 to 1.08) | 0.06 | 0.38 (0.08 to 1.68) | 0.20 |
| HCV positive (negative as reference category) | 2.43 (0.33 to 17.97) | 0.39 | ||
| CMV viremia (no viremia as reference category) | 0.05 (0 to 791) | 0.54 |
Univariable and multivariable Cox proportional hazards models were constructed for outcomes that were significant at P<0.05 level by Kaplan–Meier analysis: Model A, 10-year incidence of acute rejection; model B, 10-year incidence of death with a functioning allograft; and model C, 10-year incidence of death-censored graft loss. All multivariable models used forced entry of covariates that were significant at P<0.10 by univariable analysis. HR, hazard ratio; 95% CI, 95% confidence interval; CMV, cytomegalovirus.